226330 — Syntekabio Balance Sheet
0.000.00%
- KR₩107bn
- KR₩117bn
- KR₩121m
Annual balance sheet for Syntekabio, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 41,091 | 52,709 | 35,342 | 19,668 | 12,066 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 362 | 248 | 281 | 231 | 59.9 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 41,536 | 58,193 | 37,497 | 21,980 | 12,565 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 2,582 | 9,054 | 17,475 | 30,461 | 30,672 |
| Net Intangible Assets | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 44,778 | 67,879 | 55,689 | 52,917 | 43,715 |
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 1,037 | 1,888 | 22,254 | 19,398 | 16,301 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 3,238 | 40,252 | 24,228 | 21,688 | 18,772 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| ESOP Debt Guarantee | |||||
| Other Equity | |||||
| Total Equity | 41,540 | 27,627 | 31,461 | 31,228 | 24,943 |
| Total Liabilities & Shareholders' Equity | 44,778 | 67,879 | 55,689 | 52,917 | 43,715 |
| Total Common Shares Outstanding |